{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:57Z","timestamp":1791335637808,"version":"4.3.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jtho.2016.06.021","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T23:28:10Z","timestamp":1468538890000},"page":"1755-1764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression"],"prefix":"10.1016","volume":"11","author":[{"given":"Lysanne A.","family":"Lievense","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Bezemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretha E.H.","family":"Kaijen-Lambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P.J.J.","family":"Hegmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.06.021_bib1","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00262-011-1103-6","article-title":"Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma","volume":"60","author":"Bograd","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2016.06.021_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2012.02.034","article-title":"Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies","volume":"322","author":"Izzi","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jtho.2016.06.021_bib3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2016.06.021_bib4","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.06.021_bib5","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1165\/rcmb.2013-0472TR","article-title":"Immunotherapy for malignant pleural mesothelioma. Current status and future prospects","volume":"50","author":"Wong","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jtho.2016.06.021_bib6","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.06.021_bib7","doi-asserted-by":"crossref","first-page":"e25236","DOI":"10.4161\/onci.25236","article-title":"Immunological profiling as a means to invigorate personalized cancer therapy","volume":"2","author":"Hegmans","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2016.06.021_bib8","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1158\/0008-5472.CAN-12-3932","article-title":"Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer","volume":"73","author":"Aerts","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.06.021_bib9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccm.2013.04.007","article-title":"Intracavitary therapeutics for pleural malignancies","volume":"34","author":"Haas","year":"2013","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jtho.2016.06.021_bib10","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.06.021_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2016.06.021_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/rccm.201203-0465PP","article-title":"Malignant pleural effusion: tumor-host interactions unleashed","volume":"186","author":"Stathopoulos","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2016.06.021_bib13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that\u00a0suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2016.06.021_bib14","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2016.06.021_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4161\/cbt.4.3.1644","article-title":"Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma","volume":"4","author":"DeLong","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jtho.2016.06.021_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10555-007-9072-0","article-title":"Inflammatory cell infiltration of tumors: Jekyll or Hyde","volume":"26","author":"Talmadge","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jtho.2016.06.021_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.lungcan.2013.02.017","article-title":"Tumor-associated macrophages in thoracic malignancies","volume":"80","author":"Lievense","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.021_bib18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in\u00a0vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtho.2016.06.021_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2016.06.021_bib20","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2016.06.021_bib21","doi-asserted-by":"crossref","first-page":"e106742","DOI":"10.1371\/journal.pone.0106742","article-title":"Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma","volume":"9","author":"Cornelissen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2016.06.021_bib22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.lungcan.2013.06.005","article-title":"Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients","volume":"81","author":"Heuvers","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.021_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-1759(00)00231-3","article-title":"Analysing cell division in\u00a0vivo and in\u00a0vitro using flow cytometric measurement of CFSE dye dilution","volume":"243","author":"Lyons","year":"2000","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.jtho.2016.06.021_bib24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T cell proliferation by macrophage tryptophan catabolism","volume":"189","author":"Munn","year":"1999","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtho.2016.06.021_bib25","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4049\/jimmunol.1100889","article-title":"M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells","volume":"187","author":"Heusinkveld","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jtho.2016.06.021_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","article-title":"Macrophages, innate immunity and cancer: balance, tolerance, and diversity","volume":"22","author":"Mantovani","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jtho.2016.06.021_bib27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/1471-2407-13-324","article-title":"Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid","volume":"13","author":"Scherpereel","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2016.06.021_bib28","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/cncr.22999","article-title":"Interleukin-6 and its receptor in cancer: implications for translational therapeutics","volume":"110","author":"Hong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2016.06.021_bib29","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1172\/JCI34237","article-title":"IL-6 involvement in epithelial cancers","volume":"117","author":"Schafer","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtho.2016.06.021_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","article-title":"TGFbeta in Cancer","volume":"134","author":"Massague","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2016.06.021_bib31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGFbeta","volume":"10","author":"Flavell","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2016.06.021_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1101029","article-title":"Regulation of immune responses by prostaglandin E2","volume":"188","author":"Kalinski","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jtho.2016.06.021_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2016.06.021_bib34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/1471-2407-10-464","article-title":"COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function","volume":"10","author":"Veltman","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2016.06.021_bib35","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2016.06.021_bib36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nature Immunol"},{"key":"10.1016\/j.jtho.2016.06.021_bib37","unstructured":"Opitz I, et\u00a0al. Phase I intracavitary cisplatin-fibrin chemotherapy after resection for malignant pleural mesothelioma patients (INFLUENCE-MESO). Paper presented at the 12th International Mesothelioma Interest Group Conference. October 21\u201324, 2014; Capetown, South Africa."},{"key":"10.1016\/j.jtho.2016.06.021_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3816\/CLC.2009.n.005","article-title":"Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma","volume":"10","author":"Tsao","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.021_bib39","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A\u00a0trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma","volume":"184","author":"Sterman","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2016.06.021_bib40","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A\u00a0phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtho.2016.06.021_bib41","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A\u00a0phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.06.021_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416305986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416305986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T10:56:43Z","timestamp":1536577003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086416305986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1556086416305986"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.06.021","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2016.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}